ACRS
Aclaris Therapeutics Inc
NASDAQ: ACRS · HEALTHCARE · BIOTECHNOLOGY
$5.32
-3.71% today
Updated 2026-09-16
Market cap
$818.43M
P/E ratio
—
P/S ratio
99.58x
EPS (TTM)
$-0.53
Dividend yield
—
52W range
$2 – $7
Volume
2.1M
Aclaris Therapeutics Inc (ACRS) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$5.32
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$6.49
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 3.84% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.